This isn’t just a trade spat—it’s a direct hit on people who rely on these medications. Higher tariffs could mean pricier prescriptions, delays in getting treatments, and less money for developing new drugs. With big pharma players like Novo Nordisk already facing setbacks (as the linked article shows), this adds another layer of instability to an industry that’s already under pressure. For patients, it’s a lose-lose.

Trade group says levy will reduce access, disrupt supply chains and cut R&amp;D<ul><li><a href="https://www.theguardian.com/business/2025/jul/29/wegovy-novo-nordisk-shares-sales-maziar-mike-doustdar-eli-lily">Wegovy maker Novo Nordisk’s shares plunge on sales forecast</a></li></ul>The European pharmaceutical industry has condemned the US move to put 15% tariffs on medicines imported from the EU, calling the taxes a “blunt instrument” that would harm patients on both sides of the Atlantic.They were responding to a White House <a href="https://www.whitehouse.gov/fact-sheets/2025/07/fact-sheet-the-united-states-and-european-union-reach-massive-trade-deal/">text of the deal</a> that inferred the 15% baseline rate on imports from the EU would also apply to drugs if <a href="https://www.theguardian.com/us-news/2025/jul/27/eu-delegation-poised-for-trump-trade-talks-in-scotland">the agreement</a> is implemented on the US side on Friday as expected. <a href="https://www.theguardian.com/business/2025/jul/29/european-pharmaceutical-firms-criticise-trump-tariffs-on-medicines-as-blunt-instrument">Continue reading...</a>

European drugmakers are sounding the alarm over Trump’s new 15% tariff on medicines imported from the EU, warning it’ll hurt patients by driving up costs, disrupting supply chains, and potentially slashing funding for critical research. The industry trade group slammed the policy as a "blunt instrument" with ripple effects on both sides of the Atlantic.